China's First Intracranial Aneurysm Embolization辅助支架 Gains Market Approval, Marking a Milestone in the Billion-Dollar Neurointerventional Arena

It is worth mentioning that, currently, there are no effective methods to prevent cerebral aneurysms. However, with the development of interventional techniques and advancements in equipment, endovascular interventional treatment has shown significant advantages in reducing disability and mortality rates.Has gradually become the first choice for the treatment of intracranial aneurysms.

Among them, Stent-Assisted Coiling (SAC) is one of the mainstream interventional treatment methods for intracranial aneurysms. By deploying an intracranial stent at the neck of the aneurysm, it provides support for the coils inserted into the aneurysm cavity, effectively preventing coil migration or escape.

The SAC method is widely welcomed in clinical practice due to its advantages of good long-term effects, low recurrence rate, and high efficacy. However, before this,There are currently no domestically produced intracranial auxiliary embolization stent products available on the market in China, and reliance is solely on imports.

HeartCare's Intracranial Aneurysm Embolization Assist Stent consists of three parts: the stent, delivery wire, and introducer sheath. Its introduction has successfully broken the long-term monopoly of imported products in this field in China, not only providing Chinese patients with intracranial aneurysms a safer and more effective treatment option, but alsoThe design of this stent is more in line with the anatomical characteristics of the Chinese population., providing patients with a more suitable treatment plan.

HeartCare Intracranial Aneurysm Embolization Assist Stent

The stent portion is made from nickel-titanium alloy tubing, manufactured through laser engraving. This material not only offers excellent elasticity and plasticity but also demonstrates superior biocompatibility.Ensure the safety and stability of long-term use in the human body.

The radiopaque markers are staggered in the middle of the stent, which can not only effectively clarify the relative positional relationship between the middle of the stent and the neck of the aneurysm, ensuring that the stent provides the most effective support for the coil, but also after the stent is released,The apposition effect was observed through the middle imaging point of the stent., thereby ensuring the accuracy and safety of the surgery.

HeartCare's intracranial aneurysm embolization assist stent has an effective length of up to 60mm.Adapting to more neck options,Giving clinicians more options.

It is reported that the intracranial aneurysm embolization assist stent developed by HeartCare is led in clinical trials by Professor Jianmin Liu from the First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital). As an authoritative expert in the field of neurointervention, Professor Liu has profound academic attainments and extensive clinical experience, and his participation is undoubtedly...Ensured the scientific and rigorous nature of the clinical trials for this product.`, believing that more clinical patients will benefit in the future, pushing the development of China's neurointervention field to a new level.`

HeartCare Intracranial Aneurysm Embolization Assist Stent
↓Intent Registration↓

Against this backdrop, the continuous innovation of products becomes particularly important, especially in an environment that strongly supports domestically produced goods.Whoever can achieve a breakthrough first will reap the most substantial rewards.

However, everyone knows about innovation, but in the field of neurointervention with extremely high barriers, continuous innovation is not an easy task.

On the one handHighly innovative new technologies in the field of neurointervention will inevitably require enterprises.Invest a large amount of cost，On the other hand,Innovative and well-received but not commercially successful,Enterprises need to face the challenge of low market acceptance.

An employee of a Chinese medical device company stated that there are not many companies in the neurointerventional field that are truly profitable, making it difficult to keep up with the pace of R&D expenditure.The top priority for everyone is to survive first.

Therefore, the development of the neurointervention field has entered a new stage, shifting from the past competition of products and technology,Gradually shifting to the test of commercialization and monetization capabilities. Because only by transforming technological achievements into actual sales in the market can enterprises continuously invest in research and development, forming a virtuous cycle.

Drawing on the development experience of the coronary intervention market, we can foresee that the number of leading domestic companies the neurointervention market can eventually accommodate will not be large. The key factor that truly sets enterprises apart is...First is the company's independent R&D capability, followed by a rich product portfolio, and most importantly, the company's commercialization ability.

According to the 2023 financial report disclosed by HeartCare, the company achieved operating revenue of 232 million yuan in 2023, representing a year-on-year increase of 26.9%. The loss also decreased by 53.1% year-on-year, which is mainly attributed toThe company's continuous strengthening of the commercial sales of its marketed products, the constant expansion of sales channels, and the rapid increase in product market share., which also meansHeartCare is steadily moving forward on the right track of commercialization.

Moreover, it is worth mentioning that due to the advancement of centralized procurement and the severe homogenization of industry products, 2021 was dubbed the "winter" of the neurointerventional field. Against this backdrop, HeartCare successfully went public, achieving a leap from establishment to IPO in just five years, undoubtedly emerging as a leader in the wave of China-produced replacements in the neurointerventional field.

Firstly, in the product field, on the highly predictable golden track, a differentiated and strong product line is inevitably required to break through. With so many players entering the neurointervention track, what makes HeartCare's product line unique?

Since its establishment in 2016, HeartCare's product development has always revolved around one central focus: fully treating the condition of stroke and eliminating all contributing factors.

Therefore, HeartCare has pioneered a one-stop solution for the treatment and prevention of stroke.With a full product pipeline ranging from the treatment of acute ischemic stroke and neurovascular stenosis, ischemic stroke prevention, hemorrhagic stroke treatment to interventional access devices., with over 300 patent applications,Nearly 30 products have obtained registration certificates for domestically produced medical devices in China.

Based on a multi-pipeline product layout, HeartCare's pipeline portfolio exhibits strong synergy. Taking the core ischemic market in neurointervention as an example, HeartCare's flagship products are the thrombectomy stent and aspiration pump combination, which integrate aspiration and thrombectomy techniques.Such a product portfolio can greatly meet the clinical needs of patients in China with fine blood vessels.

In addition to expanding the number of products, in pursuit ofIn terms of product performance, HeartCare directly rivals the industry giants.

For example, its Captor, the first multi-point imaging thrombectomy stent approved for marketing in China in 2020, is对标to the latest generation platinum version of Medtronic's Solitaire in the clinical trial control group.Captor performs excellently in terms of recanalization rate, recanalization time, and safety.

It is worth mentioning that, in 2021, Medtronic sued Captor for infringing on two Chinese invention patents of Solitaire. After a year, this battle between imported and domestically produced patents ended with...HeartCare Wins Lawsuit, and behind this, the competition is not just about intellectual property,Even moreHeartCare has established an unbreakable technical barrier through continuously iterated patents, as well as a high moat facing the market.

Secondly, in terms of market expansion, although international giants have almost monopolized the market in China due to their first-mover advantage, HeartCare has successfully broken through by taking a unique path.

For stroke patients, every second is crucial. The acute onset, short treatment time window, and the unsuitability for long-distance transfer make it necessary for stroke patients to receive rapid treatment at the best-equipped local hospital, which is the county hospital. Therefore, HeartCare strongly anticipated...The grassroots market will be the future growth pole of China's neurointervention market.

In order to deeply penetrate the grassroots hospital market, HeartCare is actively expanding new market demands while consolidating its existing market advantages, promoting its products to the grassroots level.The goal is to cover 80% of the grassroots market.

In the competition of grassroots markets, product price has always been an advantage for domestically produced goods. Taking stent thrombectomy as an example, before the emergence of domestically produced devices in the neurointerventional field in 2020, the cost of a stent thrombectomy surgery was as high as 50,000 to 100,000 yuan, or even more.

HeartCare has developed a complete product system in the field of ischemic stroke thrombectomy.While ensuring quality, the price is only 60% to 70% of imported products, making it more competitive in the grassroots market.

Besides price, the education for both doctors and patients in primary healthcare is a huge challenge for China's growing device companies. Therefore,HeartCareHeartCare established a special fund for stroke to help grassroots doctors improve their skills in neurointerventional surgery and promote the penetration of neurointerventional technology into grassroots markets.

When the industry's internal competition continues to escalate, a single innovative track obviously can no longer sustain rapid development. Coupled with the continuous expansion of volume-based procurement, the development of a single track poses too high a risk for enterprises.

Therefore, in addition to its deep cultivation in the neurointervention field, HeartCare has also actively expanded its layout.Golden tracks such as electrophysiology, pulmonary intervention, surgical robotics, and peripheral intervention have completed the transformation from a single track to a platform-based enterprise., to strengthen the company's ability to withstand risks.

Obviously,Excellent product quality, forward-looking market planning, and a sustainable development blueprint,HeartCare has set a successful example for those companies deeply entrenched in the fierce competition of China's neurointerventional field.

In the future, we also believe that there will be more medical device companies like HeartCare in China's neurointervention field, excelling in comprehensive capabilities such as innovation, commercialization, and supply chain management.

The content of this article is for reference only and does not constitute investment advice. Readers are expected to effectively distinguish.If any platform reprints this article, it must take responsibility for the content of the article. Medical Device Business Review is not responsible for the impact of secondary dissemination caused by the reprint.

*Advertisement